Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 4/20 | 0.37 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.36 |
| ▸ | MERTK | Q12866 | 3/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461635 | 0.86 | CREBBP (0.45) | CREBBPAXLIRAK1MERTKPIK3CA | |
| SCHEMBL4474475 | 0.86 | IRAK1 (0.39) | CREBBPAXLIRAK1MAPK8MAPK9 | |
| SCHEMBL10227421 | 0.85 | CREBBP (0.46) | CREBBPAXLIRAK1MERTKPIK3CA | |
| SCHEMBL4465149 | 0.85 | CREBBP (0.46) | CREBBPAXLIRAK1MERTKPIK3CA | |
| SCHEMBL4458901 | 0.83 | CREBBP (0.37) | CREBBPAXLIRAK1MERTKPIK3CA | |
| SCHEMBL4453731 | 0.82 | MAPK8 (0.45) | CREBBPAXLIRAK1MERTKPIK3CA | |
| SCHEMBL4459215 | 0.81 | CREBBP (0.41) | CREBBPAXLIRAK1MERTKPIK3CA | |
| SCHEMBL2754302 | 0.78 | PDPK1 (0.41) | CREBBPMAPK8TYRO3BRD4 | |
| SCHEMBL4457497 | 0.78 | MAPK8 (0.43) | CREBBPAXLIRAK1MERTKMAPK8 | |
| SCHEMBL4454161 | 0.78 | MAPK8 (0.41) | CREBBPAXLIRAK1PIK3CAMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178552-B2 | 7-Azaindole derivatives and their use in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069354-A1 | 7-AZAINDOLE DERIVATIVES AND THEIR USE IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPK13, MAPKAPK5 | CREBBP 373/4885AXL 4101/4885IRAK1 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.